Compare Hyatt Hotels Corporation (H) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Hyatt Hotels Corporation trades at $173.03 (market cap $16.27B), while Zimmer Biomet Holdings Inc trades at $95.13 (market cap $18.55B). The key difference: Hyatt Hotels Corporation and Zimmer Biomet Holdings Inc are close in size by market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.
| H | ZBH | |
|---|---|---|
Market Cap | $16.27B | $18.55B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $107.71 |
52-Week Low | $135.42 | $79.58 |
Enterprise Value | $20.17B | $25.61B |
Dividend Yield | 0.35% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $170.08, down 4.29% on the day, reflecting a bearish technical trend with key support at $167. Fundamentally, the company shows revenue growth to $7.10B in 2025 but reported a net loss of $52M, with a high P/E ratio of 213.14 indicating premium valuation. Recent Q2 2026 earnings beat expectations with EPS of $1.12, driven by strong fee growth and RevPAR gains, as reported by Business Wire on July 30, 2026.
The outlook is mixed; analyst consensus is a 'Hold' with a $199.55 price target, suggesting 17% upside, but high debt and regional weaknesses pose risks. Investment opportunity hinges on sustained operational momentum offsetting valuation concerns, with key risks including project delays and macroeconomic pressures on travel demand.
ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.
The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
